Portolan Capital Management, LLC Halozyme Therapeutics, Inc. Transaction History

Portolan Capital Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$38.84 - $51.31 $5.68 Million - $7.5 Million	-146,239 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$39.51 - $51.45 $2.48 Million - $3.22 Million	-62,661 Reduced 30.0%	146,239 $6.1 Million
Q4 2020 Feb 16, 2021	SELL	$25.81 - $43.62 $5.09 Million - $8.59 Million	-197,034 Reduced 48.54%	208,900 $8.92 Million
Q3 2020 Nov 16, 2020	SELL	$25.74 - $29.63 $3.28 Million - $3.77 Million	-127,376 Reduced 23.88%	405,934 $10.7 Million
Q2 2020 Aug 14, 2020	BUY	$16.25 - $26.81 $3.64 Million - $6.01 Million	224,040 Added 72.44%	533,310 $14.3 Million
Q1 2020 May 14, 2020	BUY	$13.9 - $21.83 $4.3 Million - $6.75 Million	309,270 New	309,270 $5.56 Million

543

125M

294K

180K

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.62B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

Get notified when there are updates to the investment portfolio of Portolan Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Portolan Capital Management, LLC with notifications on news.